Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment
Epstein-Barr virus (EBV) is a pathogen that infects more than 90% of global human population. EBV primarily targets Blymphocytes and epithelial cells while some of them infect monocyte/macrophage, T-lymphocytes, and dendritic cells (DCs). EBV infection does not cause death by itself but the infectio...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Publishing
2017
|
Subjects: | |
Online Access: | http://eprints.sunway.edu.my/831/1/Ronald%20Teow%20Epstein%20Barr%20virus.pdf http://eprints.sunway.edu.my/831/ http://doi.org/10.1155/2017/7349268 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Sunway University |
Language: | English |
id |
my.sunway.eprints.831 |
---|---|
record_format |
eprints |
spelling |
my.sunway.eprints.8312019-04-30T08:24:09Z http://eprints.sunway.edu.my/831/ Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment Teow, Sin Yeang * Yap, Hooi Yeen * Peh, Suat Cheng * RC0254 Neoplasms. Tumors. Oncology (including Cancer) Epstein-Barr virus (EBV) is a pathogen that infects more than 90% of global human population. EBV primarily targets Blymphocytes and epithelial cells while some of them infect monocyte/macrophage, T-lymphocytes, and dendritic cells (DCs). EBV infection does not cause death by itself but the infection has been persistently associated with certain type of cancers such as nasopharyngeal carcinoma (NPC), Burkitt’s lymphoma (BL), and Hodgkin’s lymphoma (HL). Recent findings have shown promise on targeting EBV proteins for cancer therapy by immunotherapeutic approach. Some studies have also shown the success of adopting EBV-based therapeutic vaccines for the prevention of EBV-associated cancer particularly on NPC. In-depth investigations are in progress to refine the current therapeutic and vaccination strategies. In present review, we discuss the highly potential EBV targets for NPC immunotherapy and therapeutic vaccine development aswell as addressing the underlying challenges in the process of bringing the therapy and vaccination from the bench to bedside. Hindawi Publishing 2017-12-31 Article PeerReviewed text en cc_by_4 http://eprints.sunway.edu.my/831/1/Ronald%20Teow%20Epstein%20Barr%20virus.pdf Teow, Sin Yeang * and Yap, Hooi Yeen * and Peh, Suat Cheng * (2017) Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment. Journal of Pathogens. pp. 1-10. ISSN 2090-3057 http://doi.org/10.1155/2017/7349268 doi:10.1155/2017/7349268 |
institution |
Sunway University |
building |
Sunway Campus Library |
collection |
Institutional Repository |
continent |
Asia |
country |
Malaysia |
content_provider |
Sunway University |
content_source |
Sunway Institutional Repository |
url_provider |
http://eprints.sunway.edu.my/ |
language |
English |
topic |
RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
spellingShingle |
RC0254 Neoplasms. Tumors. Oncology (including Cancer) Teow, Sin Yeang * Yap, Hooi Yeen * Peh, Suat Cheng * Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment |
description |
Epstein-Barr virus (EBV) is a pathogen that infects more than 90% of global human population. EBV primarily targets Blymphocytes and epithelial cells while some of them infect monocyte/macrophage, T-lymphocytes, and dendritic cells (DCs). EBV infection does not cause death by itself but the infection has been persistently associated with certain type of cancers such as nasopharyngeal carcinoma (NPC), Burkitt’s lymphoma (BL), and Hodgkin’s lymphoma (HL). Recent findings have shown promise on targeting EBV proteins for cancer therapy by immunotherapeutic approach. Some studies have also shown the success of
adopting EBV-based therapeutic vaccines for the prevention of EBV-associated cancer particularly on NPC. In-depth investigations are in progress to refine the current therapeutic and vaccination strategies. In present review, we discuss the highly potential EBV targets for NPC immunotherapy and therapeutic vaccine development aswell as addressing the underlying challenges in the process
of bringing the therapy and vaccination from the bench to bedside. |
format |
Article |
author |
Teow, Sin Yeang * Yap, Hooi Yeen * Peh, Suat Cheng * |
author_facet |
Teow, Sin Yeang * Yap, Hooi Yeen * Peh, Suat Cheng * |
author_sort |
Teow, Sin Yeang * |
title |
Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment |
title_short |
Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment |
title_full |
Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment |
title_fullStr |
Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment |
title_full_unstemmed |
Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment |
title_sort |
epstein-barr virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment |
publisher |
Hindawi Publishing |
publishDate |
2017 |
url |
http://eprints.sunway.edu.my/831/1/Ronald%20Teow%20Epstein%20Barr%20virus.pdf http://eprints.sunway.edu.my/831/ http://doi.org/10.1155/2017/7349268 |
_version_ |
1644324412397191168 |